从支持到恢复:LVAD在逆转心力衰竭中的演变作用
1Department of Cardiac Surgery, TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences ï¿¿ Peking Union Medical College, Tianjin, 300457, China.
Journal of cardiothoracic surgery
|August 20, 2025
概括
左心室辅助装置 (LVAD) 治疗可以导致心脏恢复,允许设备被移除 (桥梁恢复). 现实数据显示出较低的移植率,强调需要更好的患者选择和优化的卸载策略,以成功恢复心脏功能.
科学领域:
- 心脏病学
- 生物医学工程
- 复原医学
背景情况:
- 左心室辅助器件 (LVAD) 越来越多地用于晚期心力衰竭.
- LVAD可以诱导心肌逆向重塑,使潜在的装置扩展 (桥梁恢复 - BTR).
- 实际的BTR比预期的研究率低得多,这表明临床实践存在差距.
研究的目的:
- 审查LVAD介导心肌恢复的当前临床和分子机制.
- 确定通往复苏的关键决定因素和挑战.
- 探索未来优化LVAD治疗心脏功能恢复的方向.
主要方法:
- 对LVAD诱导的心肌恢复的当代临床数据和分子见解的综合.
- 血液动力学和心声学标准的分析.
- 对药物和机械卸载策略及其对反向改造的影响进行审查.
主要成果:
- 成功的BTR与严格的探索标准 (例如,LVEF>45%,PCWP ≤15 mmHg) 和激进的指南导向医学治疗有关.
- 通过新陈代谢,平衡,细胞外基质和免疫路径促进反向重塑.
- 挑战包括缺乏预测性生物标志物,低于最佳的医学治疗依从性和儿科人口特异性.
结论:
- 通过优化患者选择,严格的标准和先进的治疗方法,可以实现LVAD介导的心肌恢复.
- 在预测生物标志物,标准化方案和新药疗法方面需要进一步的研究.
- 将BTR重新定义为首要目标可以改变心力衰竭的管理,从而使患者从终身设备依赖中解放出来.
相关概念视频
Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure II: Pathophysiology
38
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
38


